The Bulletin Board

New Hampshire expands access to monkeypox vaccine

By: - August 22, 2022 2:18 pm

This digitally colorized electron microscopic image depicts monkeypox virus particles. (CDC | Cynthia S. Goldsmith, Russell Regnery, Hannah Bullock)

This story was updated Aug. 22, 2022 at 3:45 p.m. with additional information from the Department of Health and Human Services.

The state is expanding access to the monkeypox vaccine to those at higher risk as a protection against contracting the disease. Until recently, the state limited the vaccine to those with confirmed cases because it had a limited supply.

As of Aug. 18, the most recent data available, New Hampshire had 16 confirmed cases, according to the Centers for Disease Control and Prevention. 

The monkeypox vaccine, initially available only to people who tested positive, is now available to at-risk populations. Several providers across the state are administering the vaccine or will be soon. (Screenshot)

The type of monkeypox virus identified in New Hampshire is not usually fatal, and most people will get better within a few weeks after developing symptoms, the Department of Health and Human Services states on its monkeypox resource website. However, people with a weakened immune system, children under 8, those with a history of eczema, and pregnant or breastfeeding women may be more likely to get seriously ill or die. 

So far, four sites – Coos Family Health in Berlin, Keady Family Practice in Claremont, White Mountain Community Center in Conway, and the Nashua Health Department – are providing the vaccine to at-risk populations. (The Nashua site is for clients who are underinsured or uninsured and live in greater Nashua.) Dartmouth Health in Lebanon and four Convenient MD locations expect to begin administering the vaccine in the next two weeks.

Health and Human Services is advising people to first ask their primary care provider if the vaccine is right for them. Providers can then refer patients to a vaccination site. Those without primary care providers can contact a site directly to make an appointment. 

Based on recommendations from the Food and Drug Administration and Centers for Disease Control and Prevention, the department is able to extend its limited supply to at-risk populations by administering a lower dose of the vaccine intradermally, between the top and bottom layers of skin on a person’s forearm. That method was found to produce the same level of antibody protection compared to a higher dose of the same vaccine given beneath the skin layers.

The department has enough vaccine for close to 2,000 people, said spokesperson Laura Montenegro.

 

Our stories may be republished online or in print under Creative Commons license CC BY-NC-ND 4.0. We ask that you edit only for style or to shorten, provide proper attribution and link to our web site. Please see our republishing guidelines for use of photos and graphics.

Annmarie Timmins
Annmarie Timmins

Senior reporter Annmarie Timmins is a New Hampshire native who covered state government, courts, and social justice issues for the Concord Monitor for 25 years. During her time with the Monitor, she won a Nieman Fellowship to study journalism and mental health courts at Harvard for a year. She has taught journalism at the University of New Hampshire and writing at the Nackey S. Loeb School of Communications.

MORE FROM AUTHOR